Barclays Upgrades Qiagen to Overweight, Raises Price Target to $55

Barclays analyst Luke Sergott has upgraded Qiagen (NYSE: QGEN) from Equal-Weight to Overweight. Additionally, the price target for Qiagen has been raised from $40 to $55.